Fatigue Management for Better Living in Rheumatic Diseases

Abstract

Fatigue is a prevalent and debilitating symptom in patients with rheumatic diseases, profoundly affecting quality of life and functional capacity. This review synthesizes current evidence regarding the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and management of fatigue in rheumatic diseases, with a focus on rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and spondyloarthropathies. We discuss recent advances, guideline-based recommendations, and practical strategies for clinicians to optimize fatigue management, enhance patient outcomes, and improve daily living for individuals with rheumatic diseases.

Introduction

Fatigue is recognized as a core symptom in most rheumatic diseases, often cited by patients as one of the most challenging aspects of their condition. Unlike transient tiredness, fatigue in rheumatic diseases is persistent, multifactorial, and not fully alleviated by rest. Understanding the mechanisms and management of fatigue is paramount for clinicians aiming to improve the holistic care and quality of life in this patient population. Recent advances in the understanding of disease processes, patient-centered approaches, and guideline-driven management have created new opportunities for targeted fatigue interventions in rheumatology practice.

Epidemiology / Disease Burden

Fatigue is reported in up to 80% of patients with rheumatic diseases, including RA, SLE, and ankylosing spondylitis (AS). Studies indicate that over half of these patients experience moderate to severe fatigue, which often exceeds pain as a barrier to daily activities. Fatigue contributes to disability, work impairment, social withdrawal, and decreased adherence to therapy. Epidemiological data highlight the chronic and relapsing nature of fatigue, with longitudinal studies showing persistent symptoms even during periods of low disease activity. The disease burden is compounded by the psychological and social impact, underscoring the urgent need for effective management strategies.

Pathophysiology

The pathogenesis of fatigue in rheumatic diseases is complex and involves an interplay between inflammatory, neuroendocrine, metabolic, and psychosocial factors. Pro-inflammatory cytokines such as TNF-α, IL-1, and IL-6 play a central role by altering neurotransmitter metabolism, hypothalamic-pituitary-adrenal (HPA) axis function, and sleep architecture. Neuroimaging studies reveal altered connectivity in brain regions associated with fatigue perception. Additionally, comorbidities such as anemia, sleep disorders, depression, and deconditioning amplify the fatigue experience. The multifactorial nature of fatigue necessitates a comprehensive, mechanism-based approach to assessment and management.

Risk Factors

Several risk factors contribute to fatigue in rheumatic diseases. High disease activity, persistent inflammation, female sex, younger age, comorbid mood disorders (depression, anxiety), sleep disturbances, obesity, and low physical activity are consistently associated with higher fatigue levels. Socioeconomic disadvantage and inadequate social support further exacerbate fatigue. Importantly, discordance between objective disease measures and patient-reported fatigue is common, highlighting the role of non-inflammatory mechanisms and individual psychosocial context in fatigue perception.

Clinical Features

Fatigue in rheumatic diseases is characterized by physical, cognitive, and emotional components. Patients describe overwhelming tiredness, lack of energy, reduced mental clarity, and emotional lability. Fatigue may fluctuate diurnally or in response to activity, stress, and disease flares. Unlike normal fatigue, it is persistent, not fully reversible with rest, and disproportionate to exertion. The multidimensional nature of fatigue necessitates structured assessment tools such as the Fatigue Severity Scale (FSS), Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF-MDQ), and visual analogue scales (VAS) to capture its impact on function and quality of life.

Diagnosis

Diagnosing fatigue in rheumatic diseases requires a systematic approach to exclude reversible causes and assess contributing factors. Clinical evaluation includes comprehensive history, assessment of disease activity, medication review, and screening for comorbidities such as anemia, hypothyroidism, sleep apnea, mood disorders, and fibromyalgia. Laboratory investigations may include complete blood count, thyroid function, inflammatory markers, and screening for vitamin deficiencies. Patient-reported outcome measures are essential for quantifying fatigue severity and monitoring response to interventions. Multidisciplinary assessment, including rheumatology, psychology, and physiotherapy, is often necessary for optimal care.

Treatment & Management

Effective management of fatigue in rheumatic diseases requires an individualized, multimodal approach. Optimization of disease control with DMARDs or biologics is foundational, as active inflammation is a key driver of fatigue. Adjunctive strategies include pharmacological interventions for comorbid conditions (e.g., antidepressants, iron supplementation), structured exercise programs, cognitive-behavioral therapy (CBT), sleep hygiene, and patient education. Regular physical activity, especially graded aerobic and resistance exercise, is supported by meta-analyses as beneficial for reducing fatigue and improving functional outcomes. Multidisciplinary interventions addressing psychosocial, behavioral, and lifestyle factors are often required for sustained improvement.

Recent Advances / Emerging Therapies

Recent years have seen significant advances in the management of fatigue in rheumatic diseases. Biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have demonstrated efficacy in reducing fatigue by controlling inflammation, as shown in large randomized controlled trials. Emerging therapies targeting neuroimmune pathways, such as Janus kinase (JAK) inhibitors, show promise in modulating central mechanisms of fatigue. Digital health interventions, including telehealth-delivered CBT and self-management apps, are being evaluated in real-world settings. Personalized medicine approaches, incorporating patient-reported outcomes and predictive biomarkers, offer the potential for tailored fatigue management strategies.

Guideline Recommendations

International guidelines, including those from EULAR and ACR, emphasize the importance of routine fatigue assessment and patient-centered care in rheumatology. Recommendations advocate for regular use of validated fatigue measures, shared decision-making, and integration of non-pharmacological interventions alongside pharmacologic therapy. Multidisciplinary collaboration and individualized goal setting are key components of guideline-based care. Clinicians are encouraged to address modifiable risk factors, optimize disease control, and empower patients through education and self-management support.

Conclusion

Fatigue is a pervasive and impactful symptom in rheumatic diseases, requiring comprehensive assessment and multifaceted management. Advances in understanding the biological and psychosocial underpinnings of fatigue have informed evidence-based interventions that can significantly improve patient well-being. Ongoing research into novel therapies and personalized approaches will further enhance fatigue management, supporting better living and functional recovery in individuals with rheumatic diseases. Clinicians should prioritize fatigue as a treatment target and leverage guideline-based strategies to optimize outcomes in this vulnerable population.